• FLT3–TAZ Signaling Drives Drug Resistance in BP-CML

  2026-09-29

  Shin et al. repositioned FLT3 as both a prognostic marker and therapeutic vulnerability in blast-phase chronic myeloid leukemia (BP-CML). Their data connect FLT3 to a JAK–STAT3–TAZ–TEAD–CD36 circuit that promotes resistance to BCR::ABL1 tyrosine kinase inhibitors, while supporting FLT3-directed combinations and ponatinib-based treatment strategies in preclinical models.

• Sorafenib: A Mechanism-to-Assay Research Guide

  2026-09-29

  Sorafenib and BAY-43-9006 connect RAF signaling, VEGFR-2 blockade, and tumor angiogenesis in one versatile cancer biology research tool. This guide translates kinase pharmacology and recent VEGFR-2 inhibitor findings into better assay design, model selection, and data interpretation.

• Auranofin: TrxR Inhibitor for Redox Research

  2026-09-28

  Auranofin is a thioredoxin reductase inhibitor that disrupts cellular redox control and supports apoptosis-focused cancer research. Product-reported benchmarks include nanomolar TrxR inhibition, suppression of Helicobacter pylori growth, and radiosensitization of murine tumor cells under defined experimental conditions.

• BFH772 (VEGFR2 inhibitor): Practical Workflow

  2026-09-28

  BFH772 is a small-molecule VEGFR2 inhibitor for research workflows examining VEGFR2-associated signaling and angiogenesis, including tumor angiogenesis models. Its water insolubility and defined kinase selectivity make it a poor fit for aqueous stock preparation or experiments that require broad-spectrum kinase inhibition.

• CCK-8 Reduces Anxiety-Like Behavior in Morphine Withdrawal

  2026-09-27

  Wen and colleagues found that cholecystokinin octapeptide (CCK-8) reduced anxiety-like behavior in morphine-withdrawal rats, with pharmacological blockade implicating CCK1 receptors and endogenous μ-opioid signaling. The findings identify a receptor-mediated interaction relevant to withdrawal-related affect, while leaving the underlying opioid release mechanism and clinical applicability unresolved.

• Cabozantinib in RCC: Reading Adaptation Over Time

  2026-09-26

  Cabozantinib (XL184) can suppress kinase signaling yet leave room for time-dependent cellular adaptation. This article explains how to interpret phosphoproteomic and motility findings in renal cell carcinoma models—and how they can guide more informative experiments.

• Dovitinib: From RTK Inhibition to Translational Insight

  2026-09-25

  Dovitinib (TKI-258, CHIR-258) offers a way to interrogate interconnected receptor tyrosine kinase signaling and apoptosis in cancer models. This article frames its broad activity as an experimental advantage—and a challenge—then outlines how to build more informative, translationally relevant studies.

• Berberine Hydrochloride in Metabolic Research

  2026-09-25

  Use Berberine hydrochloride to build controlled cell-based studies of AMPK-linked metabolic regulation, LDLR expression, and context-dependent cell-death readouts. This guide combines a practical solubility and dosing workflow with a careful comparison to recent oxidized-DNA research in acute kidney injury—without assuming the mechanisms are interchangeable.

• Meropenem Trihydrate in Resistance Research

  2026-09-24

  Use Meropenem trihydrate to connect isolate-level susceptibility testing with metabolomic studies of carbapenem resistance. A paired antibiotic-free and drug-exposed workflow helps distinguish baseline resistance-associated signatures from short-term responses to cell-wall stress.

• Live-Dead Cell Staining Kit for Viability Workflows

  2026-09-24

  Pairing Calcein-AM with Propidium Iodide separates cells with intact membranes and esterase activity from membrane-compromised cells in one readout. This guide applies the Live-Dead Cell Staining Kit to microscopy, flow cytometry, and biomaterial or drug cytotoxicity workflows, with practical controls and optimization steps.

• 25-Hydroxycholesterol Reprograms Immunosuppressive TAMs

  2026-09-23

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic signal that activates lysosomal AMPKα and reinforces STAT6-dependent ARG1 production in tumor-associated macrophages. Their findings connect macrophage cholesterol metabolism with T-cell suppression and show that targeting CH25H can improve antitumor responses, including in combination with anti-PD-1 therapy.

• Cabozantinib in RCC: From Inhibition to Adaptation

  2026-09-23

  Cabozantinib is more than a multi-kinase inhibitor: it is a useful framework for studying how tumor signaling changes over time. This thought-leadership article connects XL184 target engagement with phosphoproteomic adaptation, motility phenotypes, assay design, and translational strategy in renal cell carcinoma and medullary thyroid cancer research.

• DAPI (hydrochloride): Practical DNA Staining Guide

  2026-09-22

  DAPI (hydrochloride), also known as 4',6-diamidino-2-phenylindole hydrochloride, provides a DNA-associated fluorescence readout for fixed-cell imaging, chromosome staining, histochemistry, and selected flow-cytometry workflows. It is less suitable for unvalidated live-cell assays or absolute DNA quantitation because membrane permeability, staining conditions, sequence composition, fixation, and instrument settings can alter the signal.

• C8-HSL: From Quorum Sensing to Translational Risk

  2026-09-22

  N-octanoyl-L-Homoserine lactone, also known as C8-HSL, is more than a bacterial communication reagent: it is a controllable perturbation for connecting quorum sensing with biofilm behavior, virulence, and host-cell signaling. This thought-leadership guide translates recent lung cancer findings into practical study design, competitive assay strategy, and a cautious roadmap for infection biology research.

• Polymeric Nanoplatform Activates STING in Macrophages

  2026-09-21

  The reference study reports a mannose-modified, pH-responsive polymeric nanoplatform that co-delivers R848 and 2′,3′-cGAMP to reprogram tumor-associated macrophages and enhance phagocytosis. Its key mechanistic contribution is linking STING activation with fatty acid oxidation and SIRPα downregulation, thereby supporting combination treatment with CD47 and PD-L1 antibodies in preclinical cancer models.

8125 records 1/542 page Next 12345 下5页 Last page